vs

Side-by-side financial comparison of CORE MOLDING TECHNOLOGIES INC (CMT) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.

CORE MOLDING TECHNOLOGIES INC is the larger business by last-quarter revenue ($74.7M vs $57.6M, roughly 1.3× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 19.5%). CORE MOLDING TECHNOLOGIES INC produced more free cash flow last quarter ($-2.9M vs $-167.0M).

Core Molding Technologies, Inc. was founded in 1988 and now based in Columbus, Ohio. The company manufactures sheet molding compounds (SMC), and molds fiberglass reinforced plastics. It occupies over 1,000,000 square feet of manufacturing space and its main subsidiaries are in Matamoros, Mexico, Gaffney, South Carolina, and Cincinnati, Ohio. In 2011, Core Molding Technologies formed Core Specialty Composites, LLC.

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

CMT vs PHAT — Head-to-Head

Bigger by revenue
CMT
CMT
1.3× larger
CMT
$74.7M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+74.6% gap
PHAT
94.1%
19.5%
CMT
More free cash flow
CMT
CMT
$164.1M more FCF
CMT
$-2.9M
$-167.0M
PHAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CMT
CMT
PHAT
PHAT
Revenue
$74.7M
$57.6M
Net Profit
Gross Margin
15.2%
86.7%
Operating Margin
4.8%
Net Margin
Revenue YoY
19.5%
94.1%
Net Profit YoY
71.6%
EPS (diluted)
$0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMT
CMT
PHAT
PHAT
Q4 25
$74.7M
$57.6M
Q3 25
$58.4M
$49.5M
Q2 25
$79.2M
$39.5M
Q1 25
$61.4M
$28.5M
Q4 24
$62.5M
$29.7M
Q3 24
$73.0M
$16.4M
Q2 24
$88.7M
$7.3M
Q1 24
$78.1M
Net Profit
CMT
CMT
PHAT
PHAT
Q4 25
Q3 25
$1.9M
$-30.0M
Q2 25
$4.1M
$-75.8M
Q1 25
$2.2M
$-94.3M
Q4 24
Q3 24
$3.2M
$-85.6M
Q2 24
$6.4M
$-91.4M
Q1 24
$3.8M
Gross Margin
CMT
CMT
PHAT
PHAT
Q4 25
15.2%
86.7%
Q3 25
17.4%
87.5%
Q2 25
18.1%
87.2%
Q1 25
19.2%
86.9%
Q4 24
15.8%
87.1%
Q3 24
16.9%
85.6%
Q2 24
20.0%
81.2%
Q1 24
17.0%
Operating Margin
CMT
CMT
PHAT
PHAT
Q4 25
4.8%
Q3 25
4.4%
-30.8%
Q2 25
6.6%
-151.7%
Q1 25
4.6%
-276.5%
Q4 24
1.4%
Q3 24
4.9%
-433.0%
Q2 24
8.4%
-1055.4%
Q1 24
6.1%
Net Margin
CMT
CMT
PHAT
PHAT
Q4 25
Q3 25
3.2%
-60.5%
Q2 25
5.1%
-191.9%
Q1 25
3.6%
-330.7%
Q4 24
Q3 24
4.3%
-523.3%
Q2 24
7.2%
-1248.6%
Q1 24
4.8%
EPS (diluted)
CMT
CMT
PHAT
PHAT
Q4 25
$0.35
Q3 25
$0.22
$-0.41
Q2 25
$0.47
$-1.05
Q1 25
$0.25
$-1.31
Q4 24
$-0.01
Q3 24
$0.36
$-1.32
Q2 24
$0.73
$-1.56
Q1 24
$0.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMT
CMT
PHAT
PHAT
Cash + ST InvestmentsLiquidity on hand
$38.1M
$130.0M
Total DebtLower is stronger
$17.6M
$209.1M
Stockholders' EquityBook value
$158.2M
$-438.2M
Total Assets
$228.1M
$259.1M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMT
CMT
PHAT
PHAT
Q4 25
$38.1M
$130.0M
Q3 25
$42.4M
$135.2M
Q2 25
$43.2M
$149.6M
Q1 25
$44.5M
$212.3M
Q4 24
$41.8M
$297.3M
Q3 24
$42.3M
$334.7M
Q2 24
$37.8M
$276.2M
Q1 24
$26.6M
Total Debt
CMT
CMT
PHAT
PHAT
Q4 25
$17.6M
$209.1M
Q3 25
$18.2M
$207.1M
Q2 25
$18.8M
$205.1M
Q1 25
$19.2M
$203.2M
Q4 24
$19.7M
$201.4M
Q3 24
$20.2M
$175.7M
Q2 24
$20.6M
$174.4M
Q1 24
$21.1M
Stockholders' Equity
CMT
CMT
PHAT
PHAT
Q4 25
$158.2M
$-438.2M
Q3 25
$155.4M
$-422.5M
Q2 25
$153.5M
$-405.8M
Q1 25
$149.9M
$-338.4M
Q4 24
$147.4M
$-253.6M
Q3 24
$147.8M
$-187.1M
Q2 24
$147.5M
$-233.8M
Q1 24
$142.8M
Total Assets
CMT
CMT
PHAT
PHAT
Q4 25
$228.1M
$259.1M
Q3 25
$219.7M
$240.3M
Q2 25
$219.9M
$250.2M
Q1 25
$223.6M
$294.2M
Q4 24
$209.6M
$378.3M
Q3 24
$220.7M
$387.0M
Q2 24
$225.7M
$319.4M
Q1 24
$212.3M
Debt / Equity
CMT
CMT
PHAT
PHAT
Q4 25
0.11×
Q3 25
0.12×
Q2 25
0.12×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.14×
Q2 24
0.14×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMT
CMT
PHAT
PHAT
Operating Cash FlowLast quarter
$5.0M
$-166.8M
Free Cash FlowOCF − Capex
$-2.9M
$-167.0M
FCF MarginFCF / Revenue
-3.9%
-290.0%
Capex IntensityCapex / Revenue
10.7%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.9M
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMT
CMT
PHAT
PHAT
Q4 25
$5.0M
$-166.8M
Q3 25
$4.6M
$-14.1M
Q2 25
$3.5M
$-62.7M
Q1 25
$6.1M
$-84.9M
Q4 24
$5.0M
$-266.8M
Q3 24
$9.2M
$-63.6M
Q2 24
$15.9M
$-70.7M
Q1 24
$5.1M
Free Cash Flow
CMT
CMT
PHAT
PHAT
Q4 25
$-2.9M
$-167.0M
Q3 25
$-346.0K
$-14.1M
Q2 25
$880.0K
$-62.8M
Q1 25
$4.3M
$-84.9M
Q4 24
$509.0K
$-266.9M
Q3 24
$7.0M
$-63.6M
Q2 24
$13.0M
$-70.8M
Q1 24
$3.2M
FCF Margin
CMT
CMT
PHAT
PHAT
Q4 25
-3.9%
-290.0%
Q3 25
-0.6%
-28.6%
Q2 25
1.1%
-159.0%
Q1 25
7.0%
-297.9%
Q4 24
0.8%
-899.8%
Q3 24
9.6%
-389.0%
Q2 24
14.6%
-966.2%
Q1 24
4.1%
Capex Intensity
CMT
CMT
PHAT
PHAT
Q4 25
10.7%
0.4%
Q3 25
8.4%
0.1%
Q2 25
3.3%
0.2%
Q1 25
2.9%
0.1%
Q4 24
7.2%
0.5%
Q3 24
3.1%
0.3%
Q2 24
3.3%
0.6%
Q1 24
2.4%
Cash Conversion
CMT
CMT
PHAT
PHAT
Q4 25
Q3 25
2.44×
Q2 25
0.86×
Q1 25
2.79×
Q4 24
Q3 24
2.92×
Q2 24
2.47×
Q1 24
1.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons